6-Fluoro-1-(4-fluorophenyl)-1,4-dihydro-7(8-methyl-3,8-diazabicyclo(3.2.1)oct-3-yl)-4-oxoquinoline-3-carboxylic acid | 108437-27-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-Fluoro-1-(4-fluorophenyl)-1,4-dihydro-7(8-methyl-3,8-diazabicyclo(3.2.1)oct-3-yl)-4-oxoquinoline-3-carboxylic acid
• 英文别名: 1-p-Fluorophenyl-6-fluoro-1,4-dihydro-7-(8-methyl-3,8-diazabicyclo[3.2.1]oct-3-yl)-4-oxo-3-quinolinecarboxylic acid；6-Fluoro-1-(4-fluorophenyl)-7-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)-4-oxoquinoline-3-carboxylic acid
• CAS: 108437-27-0
• 化学式: C₂₃H₂₁F₂N₃O₃
• 分子量: 425.435
• InChiKey: PZVYAIIEIVMFHO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  64.1
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  8-methyl-3,8-diazabicyclo(3.2.1)octane dihydrochloride 、 6,7-二氟-1-(4-氟苯基)-4-氧代-1,4-二氢喹啉-3-羧酸 在 吡啶 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 反应 3.0h， 以35%的产率得到6-Fluoro-1-(4-fluorophenyl)-1,4-dihydro-7(8-methyl-3,8-diazabicyclo(3.2.1)oct-3-yl)-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  7-二氮杂双环烷基喹诺酮类化合物的合成与构效关系，包括一种新的兽药喹诺酮类抗菌药物达诺沙星。

  摘要：

  一系列被各种C8（H，F，Cl，N）和N1（乙基，环丙基，乙烯基，2-氟乙基，4-氟苯基，2,4-二氟苯基）取代基取代的新颖的6-氟-7-二氮杂双环烷基喹诺酮羧酸，以及9-氟-10-二氮杂双环烷基吡啶并苯并恶嗪羧酸，并针对一系列重要的兽医病原菌进行了抗菌活性评估。在7位（苯并恶嗪10位）研究的二氮杂双环烷基侧链包括（1S，4S）-5-甲基-2,5-二氮杂双环[2.2.1]庚烷（2），（1S，4S）-2， 5-二氮杂双环[2.2.1]庚烷（3），（1R，4R）-5-甲基-2,5-二氮杂双环[2.2.1]庚烷（4），8-甲基-3,8-二氮杂双环[3.2。 1]辛烷（5），9-甲基-3,9-二氮杂双环[4.2.1]壬烷（6），1,4-二氮杂双环[3.2.2]壬烷（7），1,4-二氮杂双环[3.3.1] ]壬烷（8）和9-甲基-3,9-二氮杂双环[3.3.1]壬烷（9）。在这些侧链中，体外效能不是

  DOI：

  10.1021/jm00082a001

文献信息

• Substituted 4-pyridone 3-carboxylic acid derivatives, method for their
  申请人：Chemie Linz Gesellschaft m.b.H.

  公开号：US05045549A1

  公开（公告）日：1991-09-03

  New 4-Pyridone derivatives of General Formula are claimed ##STR1## in which R.sub.1 is methylamino,4-fluorophenyl, 2,4-difluorophenyl, R.sub.2 is hydrogen or a sulfur atom that is joined to the ring nitrogen by an ethylene bride, X is a hydrogen or a physiologically removable ester group and Y is a base of the general formula ##STR2## In formula IIa and IIb, R.sub.3 is hydrogen, lower alkyl, benzyl, formyl, acetonyl or a moiety of the formula ##STR3## Also claimed are the addition salts of compounds of formula I with pharmaceutically acceptable inorganic or organic acids or base and/or their hydrates. Also claimed are the methods of manufacture of compounds of formula I and their use as antibacterial agents.

  通用公式的新4-吡啶酮衍生物如下所述##STR1##其中R.sub.1为甲基氨基，4-氟苯基，2,4-二氟苯基，R.sub.2为氢或通过乙烯桥与环氮原子连接的硫原子，X为氢或生理可移除的酯基，Y为通用公式的碱##STR2##在公式IIa和IIb中，R.sub.3为氢，低碳烷基，苄基，甲酰基，丙酮基或公式##STR3##的基团。还声明了公式I化合物与药用可接受的无机或有机酸或碱的加合盐和/或其水合物。还声明了公式I化合物的制备方法及其用作抗菌剂的用途。
• Substituted bridged diazabicycloalkyl quinolone carboxylic acids
  申请人：Pfizer Inc.

  公开号：US05091383A1

  公开（公告）日：1992-02-25

  Antibacterial compounds have the formula ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCl or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R.sup.2 is a bridged-diazabicycloalkyl group.

  抗菌化合物的化学式为##STR1##其中R.sup.1为氢、药用可接受的阳离子或烷基；A为CH、CF、CCl或N；Y为烷基、卤代烷基、环丙基、乙烯基、甲氧基、N-甲基氨基、对氟苯基、对羟基苯基或对氨基苯基；或者A为碳，并与Y以及A和Y连接的碳和氮一起形成一个可选取代的五至七元环；R.sup.2为桥联二氮杂环烷基基团。
• Anti-bacterial substituted bridged-diazabicycloalkyl quinolone
  申请人：Pfizer Inc.

  公开号：US04861779A1

  公开（公告）日：1989-08-29

  Antibacterial compounds have the formula ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCl or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R.sup.2 is a bridged-diazabicycloalkyl group.

  抗菌化合物的化学式为##STR1##其中R.sup.1是氢、药用可接受的阳离子或烷基；A是CH、CF、CCl或N；Y是烷基、卤代烷基、环丙基、乙烯基、甲氧基、N-甲基氨基、对氟苯基、对羟基苯基或对氨基苯基；或者A是碳，并与Y以及A和Y连接的碳和氮一起形成一个五至七元环，该环可选择性地被取代；而R.sup.2是一个桥联的二氮杂环烷基基团。
• Substituted bridged-diazabicycloalkyl quinolone carboxylic acids and
  申请人：Pfizer Inc.

  公开号：US04775668A1

  公开（公告）日：1988-10-04

  Antibacterial compounds have the formula ##STR1## wherein R.sup.1 is hydrogen, a pharmaceutically aceptable cation, or alkyl; A is CH, CF, CCl or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R.sup.2 is a bridged-diazabicycloalkyl group.

  抗菌化合物的化学式为##STR1##其中R.sup.1是氢、药用可接受阳离子或烷基；A是CH、CF、CCl或N；Y是烷基、卤代烷基、环丙基、乙烯基、甲氧基、N-甲基氨基、对氟苯基、对羟基苯基或对氨基苯基；或者A是碳，并与Y以及A和Y连接的碳和氮一起形成一个五至七元环，该环可选择性地被取代；而R.sup.2是一个桥联的二氮杂双环烷基基团。
• Substituted bridged-diazabicycloalkyl quinolone carboxylic acids
  申请人：PFIZER INC.

  公开号：EP0215650A2

  公开（公告）日：1987-03-25

  Antibacterial compounds have the formula wherein R1 is hydrogen, a pharmaceutically acceptable cation, or alkyl; A is CH, CF, CCI or N; Y is alkyl, haloalkyl, cyclopropyl, vinyl, methoxy, N-methylamino, p-fluorophenyl, p-hydroxyphenyl or p-aminophenyl; or A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five to seven membered ring which is optionally substituted; and R2 is a bridged-diazabicycloalkyl group.

  抗菌化合物具有如下式子 其中 R1 是氢、药学上可接受的阳离子或烷基；A 是 CH、CF、CCI 或 N；Y 是烷基、卤代烷基、环丙基、乙烯基、甲氧基、N-甲基氨基、对氟苯基、对羟基苯基或对氨基苯基；或 A 是碳，并与 Y 以及 A 和 Y 所连接的碳和氮一起形成任选被取代的五至七位环；R2 是桥联的二氮杂双环烷基。